NCT03743350: A trial that was reported late by Rain Therapeutics, inc
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03743350 |
|---|---|
| Title | A Phase 2 Study to Evaluate the Objective Response to Tarloxotinib Administered Intravenously to Patients With Non Small Cell Lung Cancer That Harbors Either EGFR Exon 20 Insertion or a HER2-Activating Mutation |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 28, 2019 |
| Completion date | Jan. 31, 2021 |
| Required reporting date | Jan. 31, 2022, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 3, 2020 |
| Days late | None |